ACTRN12609000640202已完成3 期
A prospective, open-label, daily wear, parallel group, randomised clinical trial assessing an investigational contact lens care solution for comfort, safety and efficacy with four commercially available contact lenses, worn bilaterally over three months, in both experienced and new contact lens wearers
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Able to read and comprehend English and give informed consent as demonstrated by signing a record of informed consent;
- •-Be at least 18 years old, male or female;
- •-Willing to comply with the wearing and clinical trial visit schedule as directed by the investigator;
- •-Have ocular health findings considered to be normal” and which would not prevent the participant from safely wearing contact lenses;
- •-Is correctable to at least 6/12 (20/40) or better in each eye with contact lenses;
- •-May be experienced or inexperienced at wearing contact lenses
排除标准
- •-Any pre-existing ocular irritation, injury or condition (including keratoconus and herpes keratitis) of the cornea, conjunctiva or eyelids that would preclude contact lens fitting and safe wearing of contact lenses;
- •-Any systemic disease that adversely affects ocular health e.g. diabetes, Graves disease, and auto-immune diseases such as ankylosing spondylitis, multiple sclerosis, Sjogrens syndrome and systemic lupus erythematosus. Conditions such as systemic hypertension and arthritis do not automatically exclude prospective participants;
- •-Use of, or a need for, concurrent category S3 and above ocular medication at enrolment and/or during the study;
- •-Use of, or a need for, any systemic medication or topical medications which may alter normal ocular findings/are known to affect a participant’s ocular health/physiology or contact lens performance either in an adverse manner or beneficial manner at enrolment and/or during the study;
- •N.B. Systemic antihistamines are allowed on an ‘as needed basis’, provided they are not used -prophylactically during the trial
- •-Eye surgery within 12 weeks immediately prior to enrolment for this trial;
- •-Previous corneal refractive surgery;
- •-Contraindications to contact lens wear;
- •-Known allergy or intolerance to ingredients in any of the study products;
- •-Currently enrolled in another clinical trial;
- •-Participation in a clinical trial within the previous 2 weeks for dispensing studies and 48 hours -between in-house studies;
- •Pregnancy*;
- •The Investigator may, at his/her discretion, exclude anyone who they believe may not be able to fulfil the study requirements, or if it is believed to be in the participant’s best interests.
- •*Formal testing of pregnancy is not required. A participant’s verbal report is sufficient
研究者
相似试验
已完成
不适用
Prospective, open labelled, randomised daily wear trial comparing the ocular response and product performance between 1 Day Acuvue Moist, 1 Day Acuvue TruEye and Acuvue Oasys contact lenses in new and experienced wearersACTRN12609000812291Alcon Laboratories120
尚未招募
不适用
Contralateral, cross over clinical trial to assess the effect of novel and commercially available contact lenses on corneal topographyContact Lens WearCorneal TopographyContact Lens WearCorneal TopographyEye - Normal eye development and functionACTRN12610000639022CIBA VISION Corporation28
已完成
4 期
An observational real world effectiveness study of Fluticasone/Formoterol FDC(Maxiflo®)Rotacaps(100/6 mcg and 250/6 mcg) when taken through Revolizer® inpatients with persistent AsthmaCTRI/2014/11/005164Cipla Ltd400
已完成
4 期
An observational real world effectiveness study of Triohale® taken through metered dose Inhaler or dry powder inhaler in patients with COPD.CTRI/2015/01/005453Cipla Ltd300
尚未招募
不适用
A study to compare efficacy and tolerability of Oral Azithromycin versus Oral Doxycycline with topical Clindamycin in subjects with moderate to severe Acne VulgarisCTRI/2018/05/013916Dr Apoorva